Clinical Trials
Building momentum in clinical evidence generation.
Tripair™ is designed to overcome challenges seen in traditional TR treatments, to enable more patients to receive life-changing care. Our clinical research has demonstrated initial safety and rapid procedure times, offering a treatment for patients who previously had no other options.
First-In-Human study
Completed in 2024
Achievements
10 patients treated (FIH n=9, CU n=1) in South Africa & Serbia
Initial safety shown with first generation device
Streamlined procedure with device times below 30 minutes
Intuitive procedure with a rapid learning curve (<2 cases per physician to be proficient)
Feasibility Study
Focus for 2025–2027
Next phase
Tripair™ will be evaluated in clinical studies across Europe, North America and Japan under a global harmonized feasibility protocol. To help patients in need, we continue to conduct compassionate use cases on patients that have no alternatives. Want to learn more about our clinical study or about participating in our compassionate use program?
Global Network of Clinical Sites
What colleagues say
[ 01 - 02 ]
“At Coramaze, you are not just building a device—you are shaping the future of tricuspid care alongside brilliant, driven people who challenge and inspire you every day.”
“Being part of the QA team at Coramaze means upholding the highest standards, every step of the way. I'm proud to work alongside a team committed to delivering a safe and meaningful solution for patients with tricuspid regurgitation.
”